TABLE 2:
Baseline characteristics of melanoma brain metastasis in 77 patients*
| Characteristic | No. (%) | No Ipilimumab | Ipilimumab | p Value |
|---|---|---|---|---|
| sex | 0.557† | |||
| F | 28 (36.4) | 17 | 11 | |
| M | 49 (63.6) | 33 | 16 | |
| age in yrs | 0.047‡ | |||
| median at diagnosis of metastasis | 61 | |||
| range | 24–89 | |||
| mean (95% CI) | 59.3 (55.1–63.4) | 53.2 (49.9–56.4) | ||
| yr of GKS | 0.478† | |||
| 2002 | 1 (13) | 1 | 0 | |
| 2005 | 4 (5.2) | 4 | 0 | |
| 2006 | 4 (5.2) | 3 | 1 | |
| 2007 | 15 (19.5) | 9 | 6 | |
| 2008 | 17 (22.1) | 9 | 8 | |
| 2009 | 20 (26.0) | 15 | 5 | |
| 2010 | 16 (20.8) | 7 | 7 | |
| location of primary melanoma | 0.327† | |||
| trunk | 36 (46.7) | 22 | 14 | |
| extremities | 19 (24 7) | 12 | 7 | |
| scalp, facial, auricular | 7 (9.1) | 6 | 1 | |
| distal acral | 7 (9.1) | 3 | 4 | |
| mucosal | 2 (2.6) | 1 | 1 | |
| unknown | 6 (7.8) | 6 | 0 | |
| chemotherapy | 0.565† | |||
| no | 29 (37.7) | 20 | 9 | |
| yes | 48 (62.3) | 30 | 18 | |
| targeted therapy | 0.056† | |||
| no | 63 (81.8) | 44 | 19 | |
| yes | 14 (18.2) | 6 | 8 | |
| received ipilimumab | ||||
| yes | 27 (35.1) | |||
| no | 50 (64.9) | |||
| FU in mos | 0.23‡ | |||
| median | 12.17 | 10.435 | 17.9 | |
| mean | 18.69 | 17.15 | 21.55 | |
| range | 1.97–72.83 | 1.97–72.83 | 6.6–50.93 | |
| WBRT | 0.26† | |||
| no | 52 (67.53) | 36 | 16 | |
| yes | 25 (32.5) | 14 | 11 | |
| alive at last FU | 0.183† | |||
| yes | 24 (31.2) | 13 | 11 | |
| no | 53 (68.8) | 37 | 16 | |
| ECOG PS | 0.56† | |||
| 0 | 45 | 27 | 18 | |
| 1 | 25 | 18 | 7 | |
| DS-GPA | 0.21† | |||
| 0–1 | 16 | 13 | 3 | |
| 2 | 27 | 19 | 8 | |
| 3 | 18 | 10 | 8 | |
| 4 | 16 | 8 | 8 | |
*
FU = follow-up.
†
Chi-square
‡
2-sided t-test.